Arockiaraj J, Balaji G S, Cherian V M, T S Jepegnanam, Thomas B P, Michael Joy S, Poonnoose P M
Spinal Disorder Surgery Unit, Department of Orthopaedics, Christian Medical College & Hospital, Vellore, Tamil Nadu, 632004, India.
Department of Orthopaedics, JIPMER, Puducherry, India.
J Clin Orthop Trauma. 2018 Mar;9(Suppl 1):S44-S48. doi: 10.1016/j.jcot.2017.12.009. Epub 2017 Dec 29.
Drug resistant tuberculosis is alarmingly on the rise especially in developing countries. Skeletal tuberculosis accounts up to 10% of all extra pulmonary tuberculosis. World Health Organisation (WHO) has not formulated guidelines for the management of Multi-drug resistant skeletal tuberculosis.
A retrospective analysis of patients treated for musculoskeletal tuberculosis was done, to study drug resistance patterns. The outcome was assessed both clinically and radiologically.898 patients were treated for skeletal tuberculosis during the period of 2006-2013 (96 months). 478 (53.2%) patients were treated for tubercular spondylitis and 420 (46.8%) for extra-spinal skeletal tuberculosis. Ninety two patients (10.2%) had documented resistance to the anti-tubercular drugs. There were 42 mono resistant tuberculosis cases (4.7%), 13 poly resistant cases (1.4%), 33 multi-drug resistant cases (MDR TB) (3.7%) and 4 (0.4%) extremely drug resistant tuberculosis cases (XDR). All the patients were treated medically as per drug susceptibility patterns and protocols. Surgery was performed when indicated in 59 (66%) cases. 85% completed their course of treatment and were successfully healed as per pre-set clinical, biochemical and radiological criteria. The remaining were lost to follow up. One patient died as a result of post op respiratory infection.
The prevalence of Multi-drug resistant tuberculosis patients in our centre was 3.7% and that of Extremely drug resistant tuberculosis cases was 0.4%. A Multi-disciplinary approach with drug susceptibility tests, sensitive drugs, and surgery if required is essential. Health education is essential to improve awareness among health care professionals about the danger of drug resistance in tuberculosis.
耐药结核病的发病率正在惊人地上升,尤其是在发展中国家。骨结核占所有肺外结核病的10%。世界卫生组织(WHO)尚未制定耐多药骨结核的管理指南。
对接受肌肉骨骼结核治疗的患者进行回顾性分析,以研究耐药模式。通过临床和放射学评估结果。在2006年至2013年(96个月)期间,有898例患者接受了骨结核治疗。478例(53.2%)患者接受了结核性脊柱炎治疗,420例(46.8%)接受了脊柱外骨结核治疗。92例患者(10.2%)记录显示对抗结核药物耐药。有42例单耐药结核病例(4.7%),13例多耐药病例(1.4%),33例耐多药病例(MDR-TB)(3.7%)和4例(0.4%)广泛耐药结核病例(XDR)。所有患者均根据药敏模式和方案进行药物治疗。在59例(66%)病例中,根据指征进行了手术。85%的患者完成了治疗疗程,并根据预先设定的临床、生化和放射学标准成功治愈。其余患者失访。1例患者因术后呼吸道感染死亡。
我们中心耐多药结核患者的患病率为3.7%,广泛耐药结核病例的患病率为0.4%。采用药敏试验、敏感药物以及必要时进行手术的多学科方法至关重要。健康教育对于提高医护人员对结核病耐药危险的认识至关重要。